Published in J Magn Reson Imaging on October 01, 2002
A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods (2008) 3.31
Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat Protoc (2009) 2.27
Uptake kinetics and biodistribution of 14C-D-luciferin--a radiolabeled substrate for the firefly luciferase catalyzed bioluminescence reaction: impact on bioluminescence based reporter gene imaging. Eur J Nucl Med Mol Imaging (2008) 1.64
Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine. Proc Natl Acad Sci U S A (2004) 1.56
Integrin targeting for tumor optical imaging. Theranostics (2011) 1.47
Bioluminescence imaging of live infected salmonids reveals that the fin bases are the major portal of entry for Novirhabdovirus. J Virol (2006) 1.45
Molecular optical imaging: applications leading to the development of present day therapeutics. NeuroRx (2005) 1.36
Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury. Am J Physiol Renal Physiol (2008) 1.36
Gaussia luciferase variant for high-throughput functional screening applications. Anal Chem (2009) 1.35
Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI. FASEB J (2008) 1.26
Molecular imaging perspectives. J R Soc Interface (2005) 1.14
Improved survival of mesenchymal stromal cell after hypoxia preconditioning: role of oxidative stress. Life Sci (2010) 1.14
Spectrally resolved bioluminescence tomography using the reciprocity approach. Med Phys (2008) 1.11
Bioluminescent imaging of melanoma in live mice. J Invest Dermatol (2005) 1.08
Antioxidants improve early survival of cardiomyoblasts after transplantation to the myocardium. Mol Imaging Biol (2009) 1.02
Novel bidirectional vector strategy for amplification of therapeutic and reporter gene expression. Hum Gene Ther (2004) 0.98
S-Gal, a novel 1H MRI reporter for beta-galactosidase. Magn Reson Med (2010) 0.98
Bioluminescent probes of sulfatase activity. Chembiochem (2010) 0.97
High-throughput quantitative bioluminescence imaging for assessing tumor burden. Methods Mol Biol (2009) 0.97
Monitoring immediate-early gene expression through firefly luciferase imaging of HRS/J hairless mice. BMC Physiol (2003) 0.96
Temporal variations of skin pigmentation in C57BL/6 mice affect optical bioluminescence quantitation. Mol Imaging Biol (2011) 0.96
In vivo serial evaluation of superparamagnetic iron-oxide labeled stem cells by off-resonance positive contrast. Magn Reson Med (2008) 0.96
Protein-engineered injectable hydrogel to improve retention of transplanted adipose-derived stem cells. Adv Healthc Mater (2012) 0.94
Computational methods for optical molecular imaging. Commun Numer Methods Eng (2009) 0.93
A 19F-NMR approach using reporter molecule pairs to assess beta-galactosidase in human xenograft tumors in vivo. NMR Biomed (2008) 0.93
Non-invasive molecular imaging for preclinical cancer therapeutic development. Br J Pharmacol (2013) 0.91
Cell-free production of Gaussia princeps luciferase--antibody fragment bioconjugates for ex vivo detection of tumor cells. Biochem Biophys Res Commun (2009) 0.90
Comparison of optical and power Doppler ultrasound imaging for non-invasive evaluation of arsenic trioxide as a vascular disrupting agent in tumors. PLoS One (2012) 0.89
Enhancing Akt imaging through targeted reporter expression. Mol Imaging (2009) 0.88
Novel molecular imaging platform for monitoring oncological kinases. Cancer Cell Int (2010) 0.87
In vivo excitation of nanoparticles using luminescent bacteria. Proc Natl Acad Sci U S A (2012) 0.84
Introduction: feature issue on phantoms for the performance evaluation and validation of optical medical imaging devices. Biomed Opt Express (2012) 0.83
Nipah virus envelope-pseudotyped lentiviruses efficiently target ephrinB2-positive stem cell populations in vitro and bypass the liver sink when administered in vivo. J Virol (2012) 0.83
Role of oxidative stress in hypoxia preconditioning of cells transplanted to the myocardium: a molecular imaging study. J Cardiovasc Surg (Torino) (2011) 0.83
In vivo detection of extrapancreatic insulin gene expression in diabetic mice by bioluminescence imaging. PLoS One (2010) 0.83
Functional multiplex reporter assay using tagged Gaussia luciferase. Sci Rep (2013) 0.83
Suicidal gene therapy in an NF-κB-controlled tumor environment as monitored by a secreted blood reporter. Gene Ther (2010) 0.81
Optical imaging probes in oncology. Oncotarget (2016) 0.81
Applications of molecular imaging. Prog Mol Biol Transl Sci (2010) 0.81
Bioluminescence tomography with Gaussian prior. Biomed Opt Express (2010) 0.81
Molecular imaging of pulmonary disease in vivo. Proc Am Thorac Soc (2009) 0.80
A novel lipid-based nanomicelle of docetaxel: evaluation of antitumor activity and biodistribution. Int J Nanomedicine (2012) 0.80
Evaluation of tumor ischemia in response to an indole-based vascular disrupting agent using BLI and (19)F MRI. Am J Nucl Med Mol Imaging (2015) 0.79
Novel S-Gal(®) analogs as (1)H MRI reporters for in vivo detection of β-galactosidase. Magn Reson Imaging (2013) 0.78
Novel split-luciferase-based genetically encoded biosensors for noninvasive visualization of Rho GTPases. PLoS One (2013) 0.78
Opening up the optical imaging window using nano-luciferin. Pharm Res (2014) 0.77
Information loss and reconstruction in diffuse fluorescence tomography. J Opt Soc Am A Opt Image Sci Vis (2012) 0.77
Bioluminescence Tomography: Biomedical Background, Mathematical Theory, and Numerical Approximation. J Comput Math (2008) 0.76
Comparison of 3 real-time, quantitative murine models of staphylococcal biofilm infection by using in vivo bioluminescent imaging. Comp Med (2014) 0.75
Imaging virus-associated cancer. Curr Pharm Des (2008) 0.75
A generalized hybrid algorithm for bioluminescence tomography. Biomed Opt Express (2013) 0.75
Molecular imaging in oncology. Cancer Imaging (2004) 0.75
In vivo monitoring of CD44+ cancer stem-like cells by γ-irradiation in breast cancer. Int J Oncol (2016) 0.75
Shedding light on bioscience. Symposium on Optical Imaging: Applications to Biology and Medicine. EMBO Rep (2003) 0.75
Non-invasive detection of spatio-temporal activation of SBE and NFAT5 promoters in transgenic reporter mice following stroke. Neuropathology (2011) 0.75
Correlation of high-resolution X-ray micro-computed tomography with bioluminescence imaging of multiple myeloma growth in a xenograft mouse model. Calcif Tissue Int (2009) 0.75
Co-Registration of Bioluminescence Tomography, Computed Tomography, and Magnetic Resonance Imaging for Multimodal In Vivo Stem Cell Tracking. Tomography (2016) 0.75
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia (2011) 5.53
Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A (2005) 4.63
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A (2005) 3.15
Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials (2007) 3.12
Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med (2012) 2.95
Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol (2010) 2.90
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol (2008) 2.84
Towards hyperpolarized (13)C-succinate imaging of brain cancer. J Magn Reson (2007) 2.57
Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res (2006) 2.46
Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol (2007) 2.39
The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med (2009) 2.32
The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia (2006) 2.30
PASADENA hyperpolarization of succinic acid for MRI and NMR spectroscopy. J Am Chem Soc (2008) 2.27
A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol (2009) 2.10
Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci U S A (2002) 1.93
Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging (2010) 1.82
Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys (2005) 1.79
Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci (2003) 1.72
Molecular imaging of Akt kinase activity. Nat Med (2007) 1.68
Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev (2006) 1.66
A methodology for registration of a histological slide and in vivo MRI volume based on optimizing mutual information. Mol Imaging (2006) 1.63
Multi-system repeatability and reproducibility of apparent diffusion coefficient measurement using an ice-water phantom. J Magn Reson Imaging (2012) 1.57
PASADENA hyperpolarization of 13C biomolecules: equipment design and installation. MAGMA (2008) 1.56
Hyperpolarized water as an MR imaging contrast agent: feasibility of in vivo imaging in a rat model. Radiology (2012) 1.54
Clinical proton MR spectroscopy in central nervous system disorders. Radiology (2014) 1.53
Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging (2002) 1.53
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia (2007) 1.50
Diffusion coefficient measurement using a temperature-controlled fluid for quality control in multicenter studies. J Magn Reson Imaging (2011) 1.50
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res (2007) 1.48
Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci U S A (2005) 1.44
Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res (2004) 1.42
Quality assurance of PASADENA hyperpolarization for 13C biomolecules. MAGMA (2008) 1.41
Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res (2011) 1.39
Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study. Int J Radiat Oncol Biol Phys (2008) 1.39
Diffusion imaging for therapy response assessment of brain tumor. Neuroimaging Clin N Am (2009) 1.38
Real-time molecular imaging of tricarboxylic acid cycle metabolism in vivo by hyperpolarized 1-(13)C diethyl succinate. J Am Chem Soc (2011) 1.36
Real-time evaluation of p53 oscillatory behavior in vivo using bioluminescent imaging. Cancer Res (2006) 1.34
Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res (2007) 1.31
Parahydrogen-induced polarization (PHIP) hyperpolarized MR receptor imaging in vivo: a pilot study of 13C imaging of atheroma in mice. NMR Biomed (2011) 1.27
Reduced glutamate neurotransmission in patients with Alzheimer's disease -- an in vivo (13)C magnetic resonance spectroscopy study. MAGMA (2003) 1.26
An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res (2007) 1.26
A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia (2008) 1.25
The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther (2004) 1.25
A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol Imaging (2003) 1.25
Dynamic imaging of emerging resistance during cancer therapy. Cancer Res (2006) 1.23
Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx (2005) 1.23
Noninvasive imaging of apoptosis and its application in cancer therapeutics. Clin Cancer Res (2008) 1.21
Inhibition of furin/proprotein convertase-catalyzed surface and intracellular processing by small molecules. J Biol Chem (2009) 1.20
Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. Clin Cancer Res (2007) 1.16
The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res (2006) 1.15
Diffusion imaging: insight to cell status and cytoarchitecture. Neuroimaging Clin N Am (2006) 1.15
Voxel-by-voxel functional diffusion mapping for early evaluation of breast cancer treatment. Inf Process Med Imaging (2009) 1.15
Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One (2011) 1.12
Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin Cancer Res (2010) 1.10
Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy. Mol Imaging (2003) 1.10
Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. Transl Oncol (2008) 1.09
Cardiovascular applications of hyperpolarized contrast media and metabolic tracers. Exp Biol Med (Maywood) (2009) 1.06
Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Mol Cancer Ther (2012) 1.06
Sodium magnetic resonance imaging of chemotherapeutic response in a rat glioma. Magn Reson Med (2005) 1.01
Nuclear localized phosphorylated FADD induces cell proliferation and is associated with aggressive lung cancer. Cell Cycle (2005) 1.01
Fluorine-19 NMR chemical shift probes molecular binding to lipid membranes. J Phys Chem B (2008) 1.00
Intravoxel water diffusion heterogeneity imaging of human high-grade gliomas. NMR Biomed (2010) 1.00
Sodium and proton diffusion MRI as biomarkers for early therapeutic response in subcutaneous tumors. Magn Reson Imaging (2006) 0.99
Comparison of apparent diffusion coefficients and distributed diffusion coefficients in high-grade gliomas. J Magn Reson Imaging (2010) 0.99
In vivo characterization of fatty acids in human adipose tissue using natural abundance 1H decoupled 13C MRS at 1.5 T: clinical applications to dietary therapy. NMR Biomed (2003) 0.99
Clinical NOE 13C MRS for neuropsychiatric disorders of the frontal lobe. J Magn Reson (2008) 0.99
Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4. Clin Cancer Res (2005) 0.99
Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity. Anal Biochem (2007) 0.98
Continuous flow Overhauser dynamic nuclear polarization of water in the fringe field of a clinical magnetic resonance imaging system for authentic image contrast. J Magn Reson (2010) 0.98
Analysis and correction of gradient nonlinearity bias in apparent diffusion coefficient measurements. Magn Reson Med (2014) 0.98
Continuous arterial spin labeling using a train of adiabatic inversion pulses. J Magn Reson Imaging (2005) 0.98
Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance. NMR Biomed (2006) 0.97
Glial dysfunction in abstinent methamphetamine abusers. J Cereb Blood Flow Metab (2009) 0.97
DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma. PLoS One (2012) 0.96
Quantitative determination of extracellular glutamine concentration in rat brain, and its elevation in vivo by system A transport inhibitor, alpha-(methylamino)isobutyrate. J Neurochem (2004) 0.94
Diffusion-weighted MRI for assessment of early cancer treatment response. Curr Pharm Biotechnol (2010) 0.94
Targeted imaging and therapy of brain cancer using theranostic nanoparticles. Mol Pharm (2010) 0.94
Molecular imaging of protein kinases. Cell Cycle (2007) 0.93
Molecular imaging of glycogen synthase kinase-3beta and casein kinase-1alpha kinases. Anal Biochem (2010) 0.92
Fast volumetric spatial-spectral MR imaging of hyperpolarized 13C-labeled compounds using multiple echo 3D bSSFP. Magn Reson Imaging (2010) 0.92
Convection enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumors. J Neurooncol (2010) 0.91
Glial uptake of neurotransmitter glutamate from the extracellular fluid studied in vivo by microdialysis and (13)C NMR. J Neurochem (2002) 0.90
Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers. Clin Cancer Res (2010) 0.90
DCE and DW-MRI monitoring of vascular disruption following VEGF-Trap treatment of a rat glioma model. NMR Biomed (2011) 0.90
Imaging proteolytic activity in live cells and animal models. PLoS One (2013) 0.89
Kinetics of glial glutamine efflux and the mechanism of neuronal uptake studied in vivo in mildly hyperammonemic rat brain. J Neurochem (2006) 0.89
Enhancing Akt imaging through targeted reporter expression. Mol Imaging (2009) 0.88
Gd-enhanced cardiovascular MR imaging to identify left ventricular pseudoaneurysm. J Cardiovasc Magn Reson (2005) 0.88
Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. J Cell Biochem (2009) 0.88
Radiosynthesis and evaluation of 5-[125I]iodoindol-3-yl-beta-D-galactopyranoside as a beta-galactosidase imaging radioligand. Mol Imaging (2009) 0.87
Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D. Clin Cancer Res (2006) 0.87
Ornithine transcarbamylase deficiency with persistent abnormality in cerebral glutamate metabolism in adults. Radiology (2009) 0.87
Molecular imaging of c-Met tyrosine kinase activity. Anal Biochem (2011) 0.87
Bioluminescence detection of cells having stabilized p53 in response to a genotoxic event. Mol Imaging (2004) 0.87
MR spectroscopy in diagnosis and neurological decision-making. Semin Neurol (2008) 0.87
Novel molecular imaging platform for monitoring oncological kinases. Cancer Cell Int (2010) 0.87
Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic study. J Neurooncol (2005) 0.87
Chronic electrographic seizure reduces glutamine and elevates glutamate in the extracellular fluid of rat brain. Brain Res (2010) 0.86
Molecular imaging of epidermal growth factor receptor kinase activity. Anal Biochem (2011) 0.86